Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Iribarren, Kristina, Bloy, Norma, Buqué, Aitziber, Cremer, Isabelle, Eggermont, Alexander, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Špíšek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2015
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839356/
https://ncbi.nlm.nih.gov/pubmed/27141345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1088631
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items